JP Patent

JP6987384B2 — ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Assigned to エージンバイオ， インコーポレイテッド · Expires 2021-12-22 · 4y expired

What this patent protects

Patent listed against Briviact.

Drugs covered by this patent

Patent Metadata

Patent number
JP6987384B2
Jurisdiction
JP
Classification
—
Expires
2021-12-22
Drug substance claim
No
Drug product claim
No
Assignee
エージンバイオ， インコーポレイテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.